| DC Field | Value | Language |
|---|
| dc.contributor.author | Lokteva, T. I. | - |
| dc.contributor.author | Rozhkov, I. S. | - |
| dc.contributor.author | Gureev, V. V. | - |
| dc.contributor.author | Gureeva, A. V. | - |
| dc.contributor.author | Zatolokina, M. A. | - |
| dc.date.accessioned | 2022-05-04T08:47:03Z | - |
| dc.date.available | 2022-05-04T08:47:03Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.citation | Correction of morphofunctional disorders of the cardiovascular system with asialized erythropoietin and arginase II selective inhibitors KUD 974 and KUD 259 in experimental preeclampsia / T.I. Lokteva [et al.] // Research Results in Pharmacology. - 2020. - Vol.6, №1.-P. 29-40. - Doi: 10.3897/rrpharmacology.6.50851. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46563 | - |
| dc.description.abstract | Therefore, the aim of the present study was to study the effectiveness of asialized erythropoietin and arginase II selective inhibitors: KUD-259 and KUD-974 in the correction of morphofunctional disorders of the cardiovascular system in experimental preeclampsia | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | arginase II selective inhibitor | ru |
| dc.subject | asialized erythropoietin | ru |
| dc.subject | preeclampsia | ru |
| dc.subject | endothelial dysfunction | ru |
| dc.title | Correction of morphofunctional disorders of the cardiovascular system with asialized erythropoietin and arginase II selective inhibitors KUD 974 and KUD 259 in experimental preeclampsia | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 6, № 1
|
